Initial clinical data on ATTR amyloidosis derive from a phase II, open-label study to evaluate the efficacy, tolerability, safety, and pharmacokinetics of oral doxycycline (100 mg twice daily) and TUDCA (250 mg three times/day) administered continuously for 12 months in patients with TTR-related amyloidosis [91]. This evidence concerns the gene TTR and amyloidosis.